TY - JOUR
T1 - Synopsis of angiogenesis inhibitors in oncology.
AU - Ellis, Lee M.
AU - Liu, Wenbiao
AU - Fan, Fan
AU - Jung, Young Do
AU - Reinmuth, Niels
AU - Stoeltzing, Oliver
AU - Takeda, Akihiko
AU - Akagi, Morihisa
AU - Parikh, Alexander A.
AU - Ahmad, Syed
PY - 2002/5
Y1 - 2002/5
N2 - Angiogenesis is a dynamic process essential for primary tumor growth and metastases. New insights into the basic understanding of the biologic processes responsible for angiogenesis have led to the characterization of potential therapeutic targets. Several strategies for the development of antiangiogenic therapeutic modalities have been employed, including agents that (1) decrease the activity of specific angiogenic factors, (2) decrease th$ activity of endothelial survival factors, (3) increase the activity of naturally occurring antiangiogenic agents, or (4) indirectly downregulate angiogenic and survivalfactor activity. Because antiangiogenic therapy is unlikely to induce tumor regression, the criteria for efficacy must be evaluated by means other than the standard response criteria used to evaluate cytotoxic chemotherapy. Further, the redundancy of molecules responsible for the angiogenic process suggests it is unlikely that a single antiangiogenic agent will provide prolonged inhibition of angiogenesis. Nevertheless, the understanding of the basic principles that drive tumor angiogenesis will lead to the development of therapies that will likely prolong survival without the toxicity associated with standard chemotherapy.
AB - Angiogenesis is a dynamic process essential for primary tumor growth and metastases. New insights into the basic understanding of the biologic processes responsible for angiogenesis have led to the characterization of potential therapeutic targets. Several strategies for the development of antiangiogenic therapeutic modalities have been employed, including agents that (1) decrease the activity of specific angiogenic factors, (2) decrease th$ activity of endothelial survival factors, (3) increase the activity of naturally occurring antiangiogenic agents, or (4) indirectly downregulate angiogenic and survivalfactor activity. Because antiangiogenic therapy is unlikely to induce tumor regression, the criteria for efficacy must be evaluated by means other than the standard response criteria used to evaluate cytotoxic chemotherapy. Further, the redundancy of molecules responsible for the angiogenic process suggests it is unlikely that a single antiangiogenic agent will provide prolonged inhibition of angiogenesis. Nevertheless, the understanding of the basic principles that drive tumor angiogenesis will lead to the development of therapies that will likely prolong survival without the toxicity associated with standard chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0036561410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036561410&partnerID=8YFLogxK
M3 - Review article
C2 - 12102576
AN - SCOPUS:0036561410
SN - 0890-9091
VL - 16
SP - 14
EP - 22
JO - Oncology (Williston Park, N.Y.)
JF - Oncology (Williston Park, N.Y.)
IS - 5 Suppl 4
ER -